Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2011 |
| End Date: | March 2013 |
A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The purpose of this study is to establish the safety of orally administered PCI-32765 in
combination with fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab
(BR) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma(SLL).
This is a Phase 1b, open-label, parallel-group, nonrandomized, multicenter study of PCI
32765 420 mg once daily oral (PO) administration in combination with 2 different
chemotherapy regimens in subjects with relapsed/refractory chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL).
We found this trial at
7
sites
601 Elmwood Ave
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2100
Strong Memorial Hospital (University of Rochester School of Medicine) In addition to offering traditional and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials